Related Experiment Videos
Membranoproliferative glomerulonephritis in childhood: factors affecting prognosis
Insights
This study on pediatric Membranoproliferative Glomerulonephritis (MPGN) found that aggressive immunosuppression improved outcomes for non-responsive patients. Key prognostic factors included hematuria, protein/creatinine ratio, and hemoglobin levels.
Area of Science:
- Nephrology
- Pediatric Nephrology
- Immunology
Background:
- Membranoproliferative glomerulonephritis (MPGN) is a significant cause of chronic kidney disease in children.
- Understanding prognostic factors is crucial for managing pediatric MPGN.
Purpose of the Study:
- To evaluate survival rates in pediatric patients with MPGN.
- To identify factors influencing renal prognosis in this cohort.
- To assess the efficacy of different immunosuppressive therapies.
Main Methods:
- Retrospective analysis of 96 pediatric MPGN patients.
- Initial treatment with oral corticosteroids.
- Subsequent treatment with cyclophosphamide and/or pulse methylprednisolone for non-responders.
- Multivariate analysis to determine prognostic factors.
Main Results:
- Initial corticosteroid remission rate was 22.9%.
- Aggressive immunosuppression achieved remission in 25.4% (cyclophosphamide) and 50.0% (pulse methylprednisolone).
- Overall 1-, 5-, and 10-year renal survival rates were 90.1%, 81.9%, and 61%, respectively.
- Hematuria, elevated urinary protein/creatinine ratio, and low hemoglobin were significant risk factors for poor renal prognosis.
Conclusions:
- More aggressive immunosuppression is warranted for steroid-unresponsive pediatric MPGN.
- Early identification and management of risk factors like hematuria, proteinuria, and anemia are vital for preventing renal failure.
Abstract:
Membranoproliferative glomerulonephritis (MPGN) is a distinctive form of chronic glomerulonephritis. We present the results of our 96 paediatric patients with MPGN, reporting the survival and factors affecting prognosis in these patients. There were 64 boys and 32 girls with an age range of 2-17 (mean 10.6 +/- 3.7) years. All patients initially received oral corticosteroid therapy; remission was achieved in 22.9%. The unresponsive 77.1% either received cyclophosphamide and/or pulse methylprednisolone; 25.4% and 50.0% of these patients entered complete remission, respectively. The overall 1-year renal survivals of the MPGN patients were 90.1%, 5-year and 10-year survival rates were 81.9% and 61%, respectively. At multivariate analysis the factors affecting renal prognosis were haematuria at presentation (p < 0.05, risk factor 3.52), urinary protein/creatinine ratio (p < 0.05, risk factor 1.06 per 1 unit) and low haemoglobin values (p < 0.05, risk factor 1.43 for each 1 g/dl decrement). We suggest that more aggressive immunosuppression therapy should be instituted in patients unresponsive to steroids and that the aforementioned risk factors are higher for the development of renal failure.